This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Eye and Immunogenetic Features of Sarcoidosis

This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: September 20, 2006
Last updated: June 30, 2017
Last verified: December 10, 2007

This study will evaluate patients with sarcoidosis to understand how the disease affects the body. Sarcoidosis is a disease that results from inflammation of body tissues. The lungs, lymph nodes in the chest, skin and eyes are most commonly affected. As the disease progresses, small lumps, or granulomas, appear in the affected tissues. In most cases, the granulomas clear up, but in cases where they do not heal and disappear, the tissues tend to remain inflamed. Eye inflammation (uveitis) associated with sarcoidosis can cause various eye diseases, sometimes leading to blindness. This study will examine the clinical, immunological and genetic features of ocular sarcoidosis.

Patients 6 years of age and older with sarcoidosis may be eligible for this study. Candidates are screened with the following procedures:

  • Completion of a questionnaire with medical, social and demographic information
  • Blood draw for laboratory tests
  • Complete eye examination, including measurement of eye pressure and dilation of the pupils to examine the back of the eye. Fluorescein angiography may be done. This test involves injecting a dye into a vein in the arm. The dye travels to the blood vessels in the eyes. A camera flashes a blue light into the eye and takes pictures of the retina that show whether the dye has leaked from the blood vessels into the retina. Other photographs of the eye may also be taken using a special camera.

Participants are followed in conjunction with their local eye doctor as required by the status of their disease. Patients whose disease is stable are seen for an initial examination and followed every 12 months for 3 years.

Sarcoidosis Uveitis

Study Type: Observational
Official Title: Ocular and Immuno-Genetic Manifestations of Sarcoidosis

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 100
Study Start Date: September 18, 2006
Estimated Study Completion Date: December 10, 2007
  Show Detailed Description


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

    1. Participants must be at least 6 years old
    2. Participants must have biopsy-proven sarcoidosis
    3. Participant must be able to consent to participating in the protocol
    4. For minors, consent by an adult will be necessary


We will exclude participants who are unable or unwilling to give blood at the designated times in the protocol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00379275

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Eye Institute (NEI)
  More Information

Publications: Identifier: NCT00379275     History of Changes
Other Study ID Numbers: 060239
Study First Received: September 20, 2006
Last Updated: June 30, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
Pulmonary Sarcoidosis
Serum Markers

Additional relevant MeSH terms:
Uveal Diseases
Eye Diseases
Lymphoproliferative Disorders
Lymphatic Diseases processed this record on September 21, 2017